Amgen drug combined with immunotherapy extends survival in lung cancer trial
The Amgen drug is currently approved for adults in the advanced stages of small cell lung cancer that has worsened despite chemotherapy, based on data showing that Imdelltra reduced the risk of death by 40%
· 10/26/2026, 1:25:53 PM· 2 min read
The Amgen drug is currently approved for adults in the advanced stages of small cell lung cancer that has worsened despite chemotherapy, based on data showing that Imdelltra reduced the risk of death by 40%
Read original story →Related stories
health
Why West Bengal’s C-Sections, at nearly 1 in 2 births, demand a hard look
health
IIT Bombay develops low-cost device to screen for anaemia, sickle cell disease
health
Most people globally face 'high genetic risk' for three common diseases: Study
health